GlassScriptPhysician profile
Nicole Holzer
NPI 1164976783
$11,948.05
in general payments reported to CMS, 2019-2025
29 companies · $2,620 in 2025
The $2,620 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,086 · 2022: $1,947 · 2023: $2,579 · 2024: $2,716 · 2025: $2,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,914.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,351.80 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,579.84 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,339.98 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,243.66 | 2021-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $880.97 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $772.62 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $669.30 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $613.61 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $471.47 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $234.22 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $228.44 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $201.14 | 2021-2022 | |
| Axsome Therapeutics, INC. | $200.10 | 2023-2025 | Auvelity |
| Corium, LLC | $194.78 | 2022-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $156.92 | 2022-2025 | Quviviq, Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $127.83 | 2023-2025 | Qelbree, Qelbree |
| Eisai INC. | $122.84 | 2021 | |
| Vanda Pharmaceuticals INC. | $114.11 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $107.03 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Indivior INC. | $65.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.29 | 2021-2022 | |
| Sage Therapeutics, LLC | $55.10 | 2021 | |
| Noven Therapeutics, LLC | $36.75 | 2023 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $33.62 | 2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $23.27 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.35 | 2025 | |
| Vertical Pharmaceuticals, LLC | $13.13 | 2024 | Relexxii |
| Sumitomo Pharma America, INC. | $13.13 | 2023 | Latuda |
| Ironshore Pharmaceuticals INC. | $12.74 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Holzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.